arrow
O

Omar Perbellini

san Bortolo Hospital
H指数:30
被引数:3,444

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study

早期伊布替尼剂量调整在CLL中的应用:EVIdeNCE真实世界研究的回顾性分析

Cancers
IF4.4
2026-04-030
OAAI
Improved Detection of Minimal Residual Disease in AML: Validation of IDH1/2 ddPCR Assays in the Perspective of Treatment with Target Inhibitors

AML中微小残留病的改进检测:IDH1/2 ddPCR检测试剂盒在靶向抑制剂治疗视角下的验证

2025-10-260
OAAI
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study

PNH克隆在Ph阴性骨髓增殖性肿瘤中的流行病学研究:一项意大利多中心研究

2025-08-220
OAAI
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia
2024-11-140
OAAI
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

V-Rbac背景下微小残留病评估,一项Fondazione Italiana Linfomi (FIL)风险定制II期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia

在FCR治疗的慢性淋巴细胞白血病的真实多中心队列中,IGHV突变患者的长期益处

2022-10-103
PRE
Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases

系统性肥大细胞增多症与骨髓增生异常/骨髓增殖性肿瘤伴环状铁粒母细胞和血小板增多症: 三例报告

2019-10-212
PREAI
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia

慢性淋巴细胞白血病BIRC3突变的生物学和临床意义

2019-08-0169
OAAI
Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia
2017-06-0115
PREAI
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naive chronic lymphocytic leukemia
2016-12-075
OAAI
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients
2016-06-0251
OAAI